Bonde Johan, Bülow Leif
Division of Pure and Applied Biochemistry, Center for Applied Life Sciences, Lund University, 221 00, Lund, Sweden.
Biotechnol Bioeng. 2015 Jul;112(7):1319-26. doi: 10.1002/bit.25556. Epub 2015 Feb 20.
Nanoparticles made from recombinant proteins offer excellent potential for several nanotechnological applications. However, only a very limited number of proteins are currently being used for such purposes due to limited availability and stability. Therefore, we have investigated the enamel matrix protein amelogenin as a new alternative protein for use as recombinant nanoparticles. Amelogenin is a robust protein that has the ability to self-assemble into nanosized particles termed nanospheres. This self-assembly property of amelogenin is highly pH-dependent, and modifications of the solubility behavior for amelogenin can be particularly important for some applications such as drug delivery, where responsiveness at a specific pH is an essential property. In this study, an amelogenin mutant library was created and used to screen amelogenin variants with modified solubility/aggregation profiles in response to externally applied pH changes. Fifty amelogenin mutants were identified and produced recombinantly, purified and characterized. Several mutants with distinct solubility profiles were obtained that could form uniform nanospheres, ranging from 30 to 60 nm in hydrodynamic diameter. The mutants displayed a shifted onset of pH-dependent aggregation compared to wild-type amelogenin. At physiological pH, some mutants formed soluble nanospheres, while others generated nanosphere aggregates, suggesting different practical uses for the different mutants. By mixing and co-assembling mutant and wild-type amelogenin at different ratios, the level of nanosphere aggregation could be tuned at a given pH. By exploring combinations of different amelogenin variants it is possible to control aggregation events in nanomedical applications where a specific pH response is required.
由重组蛋白制成的纳米颗粒在多种纳米技术应用中具有巨大潜力。然而,由于可用性和稳定性有限,目前仅有极少数蛋白质被用于此类目的。因此,我们研究了牙釉质基质蛋白釉原蛋白,将其作为一种新型替代蛋白用于制备重组纳米颗粒。釉原蛋白是一种强大的蛋白质,能够自组装成称为纳米球的纳米级颗粒。釉原蛋白的这种自组装特性高度依赖于pH值,对于某些应用(如药物递送,其中在特定pH下的响应性是一项基本特性)而言,改变釉原蛋白的溶解行为可能尤为重要。在本研究中,构建了一个釉原蛋白突变体文库,并用于筛选对外部施加的pH变化具有改变的溶解度/聚集谱的釉原蛋白变体。鉴定出50个釉原蛋白突变体,并进行重组表达、纯化和表征。获得了几个具有不同溶解度谱的突变体,它们可以形成均匀的纳米球,流体动力学直径在30至60纳米之间。与野生型釉原蛋白相比,这些突变体表现出pH依赖性聚集起始点的偏移。在生理pH下,一些突变体形成可溶性纳米球,而另一些则产生纳米球聚集体,这表明不同的突变体有不同的实际用途。通过以不同比例混合和共组装突变体和野生型釉原蛋白,可以在给定pH下调节纳米球的聚集水平。通过探索不同釉原蛋白变体的组合,有可能在需要特定pH响应的纳米医学应用中控制聚集事件。